Net Cash Provided by (Used in) Financing Activities in USD of Eiger BioPharmaceuticals, Inc. from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Eiger BioPharmaceuticals, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2016 to 2023.
  • Eiger BioPharmaceuticals, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2023 was $41,000, a 100% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $41,000, a 100% decline from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $76,955,000, a 2330% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $3,167,000, a 97% decline from 2020.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $41,000 -$45,761,000 -100% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q1 2022 $45,802,000 +$45,787,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $15,000* -$329,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q1 2020 $344,000 -$3,827,000 -92% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $4,171,000 +$4,137,000 +12168% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $34,000 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1

Eiger BioPharmaceuticals, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $41,000 -$76,914,000 -100% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2024 2023 FY
2022 $76,955,000 +$73,788,000 +2330% 01 Jan 2022 31 Dec 2022 10-K 08 Apr 2024 2023 FY
2021 $3,167,000 -$94,296,000 -97% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
2020 $97,463,000 +$39,267,000 +67% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023 2022 FY
2019 $58,196,000 -$42,787,000 -42% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
2018 $100,983,000 +$80,989,000 +405% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021 2020 FY
2017 $19,994,000 -$45,148,000 -69% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020 2019 FY
2016 $65,142,000 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.